Chlamydial Conjunctivitis – Comprehensive Medical Guide

Overview

Chlamydial conjunctivitis, also called adult inclusion conjunctivitis, is an infection of the thin membrane (conjunctiva) that covers the white part of the eye and lines the inside of the eyelids. It is caused by the bacterium Chlamydia trachomatis—the same organism that produces the most common sexually transmitted infection (STI) worldwide.

The disease typically presents as a chronic, watery or mucopurulent discharge, eyelid swelling, and a gritty sensation. It is most prevalent among sexually active adults, especially those under the age of 30, and is transmitted through direct contact with infected genital secretions that reach the eye (e.g., via hands, towels, or sexual activity involving the eye).

According to the World Health Organization (WHO), over 131 million new chlamydial infections occur each year worldwide. While ocular involvement is less common than genital disease, studies in STI clinics show that 5–10 % of adult patients with chlamydia report ocular symptoms (CDC, 2023).

Symptoms

Symptoms develop 5–14 days after exposure and may persist for weeks if untreated. Not every individual experiences every sign.

• Redness (hyperemia) – diffuse or localized to the inner eyelid.
• Watery or mucopurulent discharge – often described as “sticky” and may cause crusting on the lashes, especially upon waking.
• Gritty or foreign‑body sensation – the eye feels as if something is inside it.
• Itching or burning – mild to moderate discomfort.
• Eyelid swelling (blepharitis) – the lids become puffy.
• Conjunctival follicular reaction – small, raised nodules (follicles) on the inner surface of the eyelid, visible on slit‑lamp examination.
• Photophobia – discomfort in bright light.
• Reduced visual acuity – usually mild, but can occur if inflammation spreads to the cornea.
• Recurrent episodes – reinfection is common if the genital source is not treated.

Children can develop a related condition called trachoma, the leading infectious cause of blindness worldwide, but this guide focuses on adult ocular infection.

Causes and Risk Factors

Primary cause

The disease is caused by Chlamydia trachomatis serovars D–K, which are the same strains that cause urogenital chlamydia. Transmission to the eye occurs through:

• Direct hand‑to‑eye contact after touching infected genital secretions.
• Use of contaminated towels, washcloths, or eye makeup.
• Sexual practices that involve the eye (e.g., ocular exposure during oral-genital contact).
• Auto‑inoculation from genital infection to the conjunctiva.

Risk factors

• Sexually active age group (15–34 years) – highest prevalence of genital chlamydia.
• Multiple sexual partners or recent new partner.
• History of genital chlamydia or other STIs.
• Poor hand hygiene – especially after using the bathroom.
• Shared personal items (towels, eye cosmetics).
• Pregnancy – hormonal changes may increase susceptibility.
• Immunocompromised state – HIV infection or use of immunosuppressive medication.

Diagnosis

Accurate diagnosis combines a careful clinical exam with laboratory confirmation.

Clinical evaluation

• History taking: recent genital symptoms, sexual exposure, and onset of ocular signs.
• Slit‑lamp examination: reveals follicles on the tarsal conjunctiva, papillary reaction, and characteristic discharge.

Laboratory tests

1. Nucleic acid amplification tests (NAATs) – most sensitive (detects bacterial DNA/RNA from conjunctival swab). Preferred method per CDC guidelines.
2. Direct fluorescent antibody (DFA) staining – visualizes chlamydial elementary bodies; less commonly used now.
3. Culture on McCoy cells – gold standard historically, but takes 48–72 h and is technically demanding.
4. Serology – not useful for acute ocular infection; primarily for trachoma surveillance.

Because chlamydial conjunctivitis often co‑exists with genital infection, simultaneous testing of urine or genital swabs is recommended.

Treatment Options

Prompt antimicrobial therapy resolves symptoms in 7–10 days and prevents complications.

First‑line antibiotics

• Doxycycline 100 mg orally twice daily for 7 days – most widely used oral regimen (CDC, 2023).
• Azithromycin 1 g orally in a single dose – convenient, especially for pregnant women (category B).

Alternative regimens

• Levofloxacin 500 mg orally once daily for 7 days (if doxycycline contraindicated).
• Erythromycin 500 mg orally four times daily for 7 days (alternative for patients with severe tetracycline allergy).

Topical therapy

Topical antibiotics alone are **not** sufficient but may be added to reduce bacterial load and symptom discomfort:

• Erythromycin ophthalmic ointment 0.5 % – applied to the conjunctival sac three times daily for 7 days.
• Polymyxin B‑trimethoprim drops – adjunctive use.

Management of sexual partners

All sexual partners within the previous 60 days should receive treatment, regardless of symptoms, to prevent reinfection (partner management is a CDC recommendation).

Lifestyle and supportive care

• Warm compresses 3–4 times daily to alleviate crusting.
• Artificial tears (preservative‑free) for lubrication.
• Avoid contact lenses until the infection clears.

Living with Chlamydial Conjunctivitis

While the infection is curable, patients may need to adopt short‑term habits to speed recovery and avoid spreading the organism.

• Hand hygiene – wash hands with soap and water for at least 20 seconds before and after touching eyes.
• Separate towels and pillowcases – use a fresh, clean towel each day; wash linens in hot water (>60 °C).
• Discard eye cosmetics – mascara, eyeliner, and eye shadow can become contaminated; replace them after treatment.
• Limit eye rubbing – can reintroduce bacteria and worsen inflammation.
• Stay on medication schedule – complete the full antibiotic course even if symptoms improve.
• Follow‑up appointment – typically 1–2 weeks after starting therapy to confirm resolution.

Prevention

Prevention focuses on reducing genital chlamydia transmission and preventing auto‑inoculation.

1. Safe sexual practices – consistent condom use and limiting number of sexual partners.
2. Regular STI screening – at least annually for sexually active adults; more frequent for high‑risk groups.
3. Prompt treatment of genital chlamydia – treats the source and eliminates ocular spread.
4. Good personal hygiene – wash hands after bathroom use; avoid sharing towels, washcloths, or eye makeup.
5. Educate partners – ensure they receive testing and treatment.
6. Pregnant women – early prenatal screening for chlamydia reduces risk of neonatal ocular infection.

Complications

If left untreated, chlamydial conjunctivitis can lead to serious ocular and systemic problems.

• Corneal ulceration – infection may extend to the cornea, causing pain, blurred vision, and potential scarring.
• Conjunctival scarring and symblepharon – adhesion of the eyelid to the eyeball, limiting eye movement.
• Chronic keratoconjunctivitis – persistent inflammation that can impair vision.
• Increased risk of secondary bacterial infection – due to compromised ocular surface.
• Transmission to newborns – maternal genital chlamydia can cause neonatal conjunctivitis (ophthalmia neonatorum) within the first week of life.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Chlamydia – CDC Fact Sheet. Updated 2023.
• World Health Organization. Chlamydia trachomatis Fact Sheet. 2022.
• Mayo Clinic. Chlamydia: Symptoms and Causes. Accessed May 2024.
• Cleveland Clinic. Conjunctivitis (Pink Eye). 2024.
• American Academy of Ophthalmology. Chlamydial Conjunctivitis. Clinical practice guidelines, 2023.
• Hammerschlag, S. & Sadiq, K. “Adult Inclusion Conjunctivitis: Clinical Presentation and Management.” *Ophthalmology*, vol. 129, no. 5, 2022, pp. 602‑608.